[3-(2-Chloro-oxazol-5-yl)-phenyl]-(4-methyl-pyrimidin-2-yl)-amine → 1-(2-Methoxy-ethyl)-4-{5-[3-(4-methyl-pyrimidin-2-ylamino)-phenyl]-oxazol-2-yl}-piperazin-2-one

Participants

Reaction Steps

Prepared as for 5-[6-(4-methylpyridin-2-ylamino)pyridin-2-yl]-N-(pyridin-4-ylmethyl)oxazol-2-amine above from [3-(2-chloro-oxazol-5-yl)-phenyl]-(4-methyl-pyrimidin-2-yl)-amine and 1-(2-methoxy-ethyl)-2-oxopiperazine trifluoroacetic acid salt in iPrOH. 1H NMR (400 MHz, DMSO-d6) δ 9.56 (s, 1H), 8.35 (d, J=5.0 Hz, 1H), 8.10 (s, 1H), 7.64 (d, J=8.0 Hz, 1H), 7.31-7.20 (m, 2H), 7.15 (d, J=7.6 Hz, 1H), 6.76 (d, J=5.0 Hz, 1H), 4.10 (s, 2H), 3.79-3.72 (m, 2H), 3.58-3.46 (m, 6H), 3.25 (dd, J=2.7, 2.2 Hz, 3H), 2.38 (s, 3H). (ESI+) m/z 409 (M+H)+. Retention time=2.94 mins (method 1).

Provenance & Evidence